Sintilimab combined with axitinib in the treatment of advanced chromophobe renal cell carcinoma: a case report

Chromophobe renal cell carcinoma (ChRCC) is a rare pathological type of renal cell carcinoma (RCC). Related systematic studies involving large numbers of patients are lacking, and more importantly, there is currently no international consensus on post-line treatment guidelines for ChRCC. The rapid d...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Huimin Zhang, Xiaofeng Cong, Chen Chen, Ziling Liu
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Frontiers Media S.A. 2024-02-01
Цуврал:	Frontiers in Oncology
Нөхцлүүд:	chromophobe renal cell carcinoma sintilimab axitinib second-line treatment long survival
Онлайн хандалт:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1325999/full
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!